SEMA, as a treatment for obesity, has shown nephroprotective effects, with a 22% reduction in the composite renal endpoint in the SELECT33 trial in patients without diabetes, supporting the role of SEMA in the management of the cardio-renal-metabolic syndrome
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP and GLP-1 receptor agonist that some patients report causes tiredness, particularly during initial treatment weeks
Nitric oxide functions as a signaling molecule involved in vasodilation, blood flow, and tissue repair
Schedule your consultation today and begin your journey with Bonnie and the Independent Wellness team
We adhere to the highest level of safety protocols, working with reputable pharmacies and registered medical professionals